Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein

Cancer Research

Volumn 74, Issue 11, 2014, Pages 3127-3136

  Ding, Zhiyong ^a   German, Peter ^a   Bai, Shanshan ^a   Reddy, A Srinivas ^a   Liu, Xian De ^a   Sun, Mianen ^a   Zhou, Lijun ^a   Chen, Xiaohua ^a   Zhao, Xiaobei ^b   Wu, Chengbiao ^b   Zhang, Shuxing ^a   Mills, Gordon B ^a   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; ELONGIN B; ELONGIN C; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VON HIPPEL LINDAU PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; ELONGIN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; MUTANT PROTEIN; PROTEASOME; TRANSCRIPTION FACTOR; VHL PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC ANALYSIS; GENETIC PROCEDURES; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OXYGEN TENSION; PHARMACOLOGICAL PROCEDURES; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; RESIDUAL VOLUME; ANIMAL; GENETICS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOGENESIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; MICE; MICE, NUDE; MUTANT PROTEINS; MUTATION, MISSENSE; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSCRIPTION FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84902170698     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3213     Document Type: Article

References (39)

1. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-67.
2. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 1999;96:12436-41.
3. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999;13:1822-33.
4. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2: 423-7.
5. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: identification of potential driver and passenger mutations. Cancer Res 2011;71:5500-11.
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
7. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
9. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2012;378:1931-9.
10. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28: 1061-8.
11. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66:2000-11.
12. Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, et al. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene 2009;28:1694-705.
13. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH. Contrasting effects on HIF-1alpha regulation by disease- causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10: 1029-38.
14. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995;269:1444-6.
15. Chung J, Roberts AM, Chow J, Coady-Osberg N, Ohh M. Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway. Oncogene 2006;25:3079-83.
16. Bangiyeva V, Rosenbloom A, Alexander AE, Isanova B, Popko T, Schoenfeld AR. Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer 2009;9:229.
17. Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS One 2008;3:e3801.
18. Hu CD, Kerppola TK. Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis. Nat Biotechnol 2003;21:539-45.
19. Ding Z, German P, Bai S, Feng Z, Gao M, Si W, et al. Agents that stabilize mutated von hippel-lindau (VHL) protein: results of a high throughput screen to identify compounds that modulate VHL proteostasis. J Biomol Screen 2012;17:572-80.
20. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, et al. A retrovirusbased protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A 2006;103: 15014-9.
21. Liu XD, Ko S, Xu Y, Fattah EA, Xiang Q, Jagannath C, et al. Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 2012;287:19687-98.
22. Maranchie JK, Zhan Y. Nox4 is critical for hypoxia-inducible factor 2- Alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. Cancer Res 2005;65:9190-3.
23. Kolacsek O, Krizsik V, Schamberger A, Erdei Z, Apati A, Varady G, et al. Reliable transgene-independent method for determining Sleeping Beauty transposon copy numbers. Mobile DNA 2011; 2:5.
24. Lukasiak P, Antczak M, Ratajczak T, Bujnicki JM, Szachniuk M, Adamiak RW, et al. RNAlyzer-novel approach for quality analysis of RNA structural models. Nucleic Acids Res 2013;41:5978-90.
25. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res 2000;28: 235-42.
26. Van Molle I, Thomann A, Buckley DL, So EC, Lang S, Crews CM, et al. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1alpha protein-protein interface. Chem Biol 2012;19:1300-12.
27. Reddy AS, Jalahalli V, Kumar S, Garg R, Zhang X, Sastry GN. Analysis of HIV protease binding pockets based on 3D shape and electrostatic potential descriptors. Chem Biol Drug Des 2011;77:137-51.
28. Dehouck Y, Kwasigroch JM, Gilis D, Rooman M. PoPMuSiC 2.1: A web server for the estimation of protein stability changes upon mutation and sequence optimality. BMC Bioinformatics 2011;12:151.
29. Feldman DE, Spiess C, Howard DE, Frydman J. Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding. Mol Cell 2003;12:1213-24.
30. Carreau A, Hafny-Rahbi BE, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 2011;15:1239-53.
31. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010;140:313-26.
32. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499: 43-9.
33. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
34. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2: 401-4.
35. Shin DH, Li SH, Chun YS, Huang LE, Kim MS, Park JW. CITED2 mediates the paradoxical responses of HIF-1[alpha] to proteasome inhibition. Oncogene 2007;27:1939-44.
36. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004;22:3720-5.
37. Feldman DE, Thulasiraman V, Ferreyra RG, Frydman J. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol Cell 1999;4:1051-61.
38. McClellan AJ, Scott MD, Frydman J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 2005;121:739-48.
39. Yang C, Huntoon K, Ksendzovsky A, Zhuang Z, Lonser RR. Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep 2013;3:52-9.